Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced the close of an extension to its Series B financing round, bringing the total amount raised to $72 million. Renibus' investors are comprised of existing and new investors, including leaders in the cardiac surgery community.
Who to call at Renibus Therapeutics, and when
A new round usually means Renibus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Renibus Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Renibus Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Renibus Therapeutics
Location
Southlake, Texas, United States
About
Renibus is a clinical-stage biopharmaceutical company focused on preventing disease progression, protecting against organ damage, and improving outcomes in cardiorenal diseases. Its pipeline includes first-in-class therapies that activate cytoprotective pathways. Lead candidate RBT-1, currently in Phase 2 for cardiac surgery, will enter Phase 3 trials to reduce complications post-cardiothoracic surgery. Other programs include RBT-2 for slowing CKD progression, RBT-3 for preventing cisplatin-induced nephrotoxicity, and RBT-9, an anti-inflammatory compound that showed promise in reducing hospital stays in COVID-19 patients.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Renibus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
SouthlakeBiotechnologyHealthcareHealth CareMedicalTherapeuticsBiopharma